In non-small cell lung cancer (NSCLC), KRAS G12C represents the most prevalent KRAS mutation subtype, accounting for approximately 11–16% of all NSCLC cases and 13% of lung adenocarcinomas specifically [5]. This evidence concerns the gene KRAS and lung adenocarcinoma.